Skip to content
Biotech For FIRE
  • Biotech
  • Holorogy
  • Investing
  • Book Review
  • News
  • About Me
  • Subscribe
  • Contact

incyte

  • Home
  • incyte

Incyte – Opzelura launch and downfall of mighty biotech into a low quality spec pharma – ARE BAKER BROS SELLING OUT OF INCYTE?

Posted by By biotechwarrior February 13, 2022Posted inTalking about BiotechNo Comments
Incyte was one of the most innovative biotech companies in the world. Jakafi (ruxolitinib) changed the lives of patients that are suffering from 1) polycythemia vera, 2) myelofibrosis, and GVHD.…
Read More
Recent posts
  • Pharma update: Bullish for 4Q24
  • Immunology market update (positive: $ABBV $UCB / negative: $JNJ, $NVS, $LLY, $BMY, $AMGN)
  • REGN’s CRL and its impact on wet AMD market: 2H23 Biotech/Pharma outlook
  • 2H23 Pharma/Biotech Outlook (Part. 1)
  • $RPRX: Curious case of insider activities at Royalty Pharma (CEO buying, but everyone else is selling)

Loading
Follow Us
  • X
About Me
Logo
Former Biotech hedge fund analyst turned internet writer. Biotech can be fun and help with our FIRE plan. Still got a long way to go and wanted to share my journey. I am a Baker Brother wannabe. You can reach me at biotechwarrior@biotechforfire.tech
Subscribe for the latest posts

Loading
Useful Links
  • Endpoints News
  • FiercePharma
  • FierceBiotech
Copyright 2026 — Biotech For FIRE. All rights reserved. Sinatra WordPress Theme
Scroll to Top